89 annotations
Page 2 of 5
It's more just overall performance across many, many nodes of our supply network.
(No comment added)
Transcript
2024 Q2
9 Aug 24
now come off the FDA shortage list
(No comment added)
Transcript
2024 Q2
9 Aug 24
Concord is doing well against its time schedule, and we expect product out of that site end of this year, early next year
(No comment added)
Transcript
2024 Q2
9 Aug 24
I wouldn't read through that the Q2 step-up in volume we shipped was primarily to RTP
(No comment added)
Transcript
2024 Q2
9 Aug 24
hey certainly open up a node of the most constrained part of the supply chain
(No comment added)
Transcript
2024 Q2
9 Aug 24
can you quantify for us where you are in the ramp in RTP?
(No comment added)
Transcript
2024 Q2
9 Aug 24
probably the most meaningful part of that will show up in the early '25 to be honest, as that new form ramps and details on that rollout will be coming in the coming weeks
(No comment added)
Transcript
2024 Q2
9 Aug 24
expect continued expansion ahead
(No comment added)
Transcript
2024 Q2
9 Aug 24
Based on the midpoint of the range, our updated guidance implies revenue growth of 38% in the second half of the year, [ below ] 31% in the first half. In the second half of the year, we expect a more significant growth in Q4 compared to Q3.
(No comment added)
Transcript
2024 Q2
9 Aug 24
production of salable doses of incretin medicines in the second half of 2024 will be at least 1.5x the salable doses taken half of 2023
(No comment added)
Transcript
2024 Q2
9 Aug 24
We are making near-term progress to ramp production, including at new sites like Research Trial Park
*in North Carolina
Transcript
2024 Q2
9 Aug 24
Significant advances in our pipeline include the approval of Kisunla for Alzheimer's disease, the submission of tirzepatide for moderate to severe obstructive sleep apnea and obesity in the U.S. and Europe and positive results from the Phase III study of tirzepatide for heart failure with preserved injection fraction and obesity.
(No comment added)
Transcript
2024 Q2
9 Aug 24
The overall safety profile of tirzepatide in the SUMMIT trial was consistent with previously reported tirzepatide studies, including SURMOUNT and SURPASS.
(No comment added)
Transcript
2024 Q2
9 Aug 24
mean body weight reduction of 15.7% compared to 2.2% for placebo
(No comment added)
Transcript
2024 Q2
9 Aug 24
tirzepatide significantly improved heart failure symptoms and physical limitations compared to placebo
(No comment added)
Transcript
2024 Q2
9 Aug 24
tirzepatide reduced the risk of worsening heart failure by 38% compared to placebo
(No comment added)
Transcript
2024 Q2
9 Aug 24
our data supporting stopping of Kisunla therapy when amyloid plaques are removed to minimal levels
(No comment added)
Transcript
2024 Q2
9 Aug 24
We note that Kisunla is broadly covered for Medicare patients through approved CED registries.
(No comment added)
Transcript
2024 Q2
9 Aug 24
Following the July approval, we launched Kisunla, and we're delighted to see that patients have already begun receiving this new Lilly medicine
(No comment added)
Transcript
2024 Q2
9 Aug 24
positive data of tirzepatide in OSA
(No comment added)
Transcript
2024 Q2
9 Aug 24